Therapeutic or Preventive Procedure
ACC25: Merck & Co.’s Winrevair reduces mortality in most severe PAH patients
Pulmonary arterial hypertension, Winrevair, Severe (severity modifier), Mortality Vital Statistics
Transcend’s neuroplastogen posts positive mid-stage results in PTSD
TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5
BiomX’s phage therapy shows promise in Phase II diabetic foot infections study
BX211, Phage Therapy, DFO
Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital
Biotech Restructuring and European Regulatory Setbacks
LifeMine Therapeutics, layoffs, PTC Therapeutics, Translarna, Duchenne muscular dystrophy, European Commission, regulatory decision
Vertexs second-generation diabetes cell therapy fails early-stage study
Failed, VX-264, Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
Galatea Bio’s $25M Funding Boost for Global Biobank and AI-Driven Genomic Research
Galatea Bio, global biobank, AI-enabled genomic analysis, precision medicine, non-European ancestry, genetic diversity